The Psychopharmacology Institute, recently published a new multimedia tutorial on the mechanism of action and formulations of methylphenidate.
This publication has an embedded video discussing the mechanism of action (role of the prefrontal cortex in NE and DA release in ADHD). You can also learn about the different methylphenidate formulations (short-acting, intermediate-acting, and long-acting). This is an illustrated tutorial that will makes things easier for you.
Methylphenidate for ADHD: Mechanism of Action and Formulations
The psychiatry website Psychopharmacology Institute has recently published an interview on treatment-resistant OCD. The expert explains that aripiprazole and risperidone are more effective in OCD than for example quetiapine and olanzapine.
He also explains a stepped approach for the pharmacotherapy of OCD
This tutorial explains the key differences and simliarites between venlafaxine and desvenlafaxine.
- They are similar in terms of efficacy, pharmacodynamics and side effects profile.
- There are differences in pharmacokinetic aspects and dosing guidelines.
Bupropion, a dopamine norepinephrine reuptake inhibitor, is approved for smoking cessation, major depressive disorder and seasonal affective disorder.
The Psychopharmacology Institute website has published an illustrated tutorial on the clinical psychopharmacology of bupropion.
- Mechanism of action
- Side effects
- Dosing guidelines
The Psychopharmacology of Bupropion: An Illustrated Overview
The Psychopharmacology Institute recently published a short summary on the main side effects of SSRIs.
Click here to view: Adverse Effects of SSRIs
This presentation explores the most relevant features of Neuropsychiatric Systemic Lupus Erythematosus:
- CNS Lupus
- NPSLE based on the revised ACR criteria
- NPSLE specific antibodies
- Imaging: MRI
- Therapeutic approach in CNS lupus – mild disease
- Therapeutic approach in CNS Lupus – severe CNS disease: diffuse/nonthrombotic disease